As of May 27
| 0.00 / 0.00%|
The 6 analysts offering 12-month price forecasts for Five Prime Therapeutics Inc have a median target of 49.00, with a high estimate of 55.00 and a low estimate of 41.00. The median estimate represents a +9.13% increase from the last price of 44.90.
The current consensus among 7 polled investment analysts is to Buy stock in Five Prime Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.